Newsroom Articles

Through their stories, families, advocates and experts paint a vivid picture of what life with Angelman syndrome looks like – the obstacles, the triumphs and the moments of strength that define their journeys. They share their experiences navigating the path to diagnosis, the hallmark signs and symptoms of AS and, most importantly, the incredible joy that their children with AS bring to their lives. 

Rick has experienced symptoms of FCS his entire life. He has been hospitalized more times than he can count with acute pancreatitis and describes it as the most pain he has ever been in. Despite these challenges, Rick is hopeful about the future for people living with this rare and severe disease and passionate about helping other people with FCS.

Recognizing our industry-leading scientific innovation and company culture, Science magazine ranked Ionis their #2 Top Employer in 2025.

In celebration of Brett Monia, Ph.D., recipient of the 2025 Oligonucleotide Therapeutics Society (OTS) Lifetime Achievement Award, colleagues and peers reflect on his extraordinary impact on science, leadership and patient care.

Hear Dr. Sam Tsimikas, SVP of Global Cardiovascular Development, share how Ionis is redefining cardiometabolic care.

Endpoints News honors Ionis’ Holly Kordasiewicz, Ph.D., SVP, Neurology for her leadership, scientific impact and commitment to advancing diversity in biopharma

Championing an investigational medicine to make a meaningful difference in the lives of those living with HAE

Ionis is proud to announce that we have ranked #6 on the San Diego Business Journal’s 2025 Best Places to Work list in the Large Companies category. This marks our second consecutive year being recognized and our first year breaking into the Top 10…

Each year, the Family Heart Foundation, a patient-advocacy organization dedicated to increasing early diagnosis and treatment of lipoprotein(a) and familial hypercholesterolemia, recognizes individuals whose contributions have reshaped…

Ionis CEO Brett Monia, Ph.D. shares the journey to becoming a fully integrated biotech, advancing RNA-targeted medicines and delivering greater impact for patients.